KLAL significantly affected by adverse events

Article

Keratolimbal allograft (KLAL) transplantation is affected by adverse events including immunologic rejections, chronic ocular surface exposure and graft-related complications, according to a study featured in Cornea.

Keratolimbal allograft (KLAL) transplantation is affected by adverse events including immunologic rejections, chronic ocular surface exposure and graft-related complications, according to a study featured in Cornea.

A retrospective, observational case series, led by Dr A. Baradaran-Rafii, Ophthalmic Research Centre, Labbafinejad Medical Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran, included assessing the medical charts of 45 patients with at least six months of follow-up. Main outcome measures were postoperative complications including graft thickness, position and alignment and immunologic rejection.

A total of 66 KLALs were performed on 45 eyes and primary failure occurred in five eyes due to ocular surface exposure and severe dry eyes. Four eyes experienced misalignments, four eyes presented with buttonhole, a further four eyes had inner-edge tear, two had inadvertent limbal trephination and two had thick KLAL.

After KLAL, eight eyes presented with regional thinning of the graft due to exposure, regional ischemia and after epithelial rejection. There were 16 cases of acute rejection in eight eyes, whereas chronic rejection was seen in 24 eyes.

At the final follow-up 12 eyes had failed because of recurrent acute rejection, chronic rejection, refractory herpetic keratitis, exposure and refractory papillomavirus keratitis. The most significant complications were identified as immunologic rejections, chronic ocular surface exposure and graft-related complications.

To read the paper please click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.